Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. Aneuploidy increases resistance to chemotherapeutics by antagonizing cell division

Aneuploidy increases resistance to chemotherapeutics by antagonizing cell division

Thumbnail Image
Download
Name

30566.full.pdf

Description
Published version
Size

1.17 MB

Format

Adobe PDF

Checksum (MD5)

900d343c7e1dbd57d07c37fae1fbbb63

sword-2021-08-05T14:50:06.original.xml (130 B)
Original SWORD entry document
Author(s)
Replogle, John Michael
•
Zhou, Wen
•
Amaro, Adrianna E
•
McFarland, James M
•
Villalobos-Ortiz, Mariana
•
Ryan, Jeremy
•
Letai, Anthony
•
Yilmaz, Omer
•
Sheltzer, Jason
•
Lippard, Stephen J
more
Date Issued
2020
Journal
Proceedings of the National Academy of Sciences of the United States of America
Publisher
Proceedings of the National Academy of Sciences
Version
Final published version
Abstract
© 2020 National Academy of Sciences. All rights reserved. Aneuploidy, defined as whole chromosome gains and losses, is associated with poor patient prognosis in many cancer types. However, the condition causes cellular stress and cell cycle delays, foremost in G1 and S phase. Here, we investigate how aneuploidy causes both slow proliferation and poor disease outcome. We test the hypothesis that aneuploidy brings about resistance to chemotherapies because of a general feature of the aneuploid condition—G1 delays. We show that single chromosome gains lead to increased resistance to the frontline chemotherapeutics cisplatin and paclitaxel. Furthermore, G1 cell cycle delays are sufficient to increase chemotherapeutic resistance in euploid cells. Mechanistically, G1 delays increase drug resistance to cisplatin and paclitaxel by reducing their ability to damage DNA and microtubules, respectively. Finally, we show that our findings are clinically relevant. Aneuploidy correlates with slowed proliferation and drug resistance in the Cancer Cell Line Encyclopedia (CCLE) dataset. We conclude that a general and seemingly detrimental effect of aneuploidy, slowed proliferation, provides a selective benefit to cancer cells during chemotherapy treatment.
MIT Department
Koch Institute for Integrative Cancer Research at MIT
Massachusetts Institute of Technology. Department of Chemistry
Howard Hughes Medical Institute
Terms of Use
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Persistent DSpace Link
https://hdl.handle.net/1721.1/133334
DOI of Published Version
https://doi.org/10.1073/pnas.2009506117
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.